Zealand Pharma is set to make a series of restructuring changes that will shake-up a number of positions at the firm.
The R&D arm of Zealand will be split into two parts, each with direct representation in management, while investor relations and communications will also be represented directly at management level.
As a result of the restructuring, the former positions of chief scientific officer and chief operating officer have become redundant.
Adam Steensberg, VP for development, has been promoted and appointed to the new position as senior VP for development and chief medical officer.
The new position as senior VP for research will temporarily be filled by Keld Fosgerau, currently VP for research, while the company searches for a permanent appointment.
Hanne Leth Hillman, VP for investor relations and corporate communications is promoted, and appointed to the new position as senior VP for investor relations and communications.
The reorganisation aims to “eliminate one management level in support of the company’s strategy” and to “ensure a dynamic organisation with operational flexibility and short decision-making”.
Britt Meelby Jensen, president and CEO of Zealand, said: “I wish Adam, Keld and Hanne every success in their new roles and I look forward to working with them in their new roles.”